Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy

Neurology
3
Pipeline Programs
1
Companies
1
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
CENOBAMATEApproved
cenobamate
Unknown Company
SK Life Science
XCOPRIApproved
cenobamate
SK Life Science
oral2019

Competitive Landscape

1 companies ranked by most advanced pipeline stage

SK Life Science
SK Life ScienceNJ - Paramus
1 program
1
1
CenobamatePhase 31 trial
Active Trials
NCT03961568Enrolling By InvitationEst. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SK Life ScienceCenobamate

Clinical Trials (1)

NCT03961568SK Life ScienceCenobamate

Cenobamate Open-Label Extension Study for YKP3089C025

Start: Aug 2019Est. completion: Aug 2026
Phase 3Enrolling By Invitation

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
11h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
11h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
12h ago

Director of Finance

CoMind
London, UK
12h ago

Electronics Engineering Manager

CoMind
London, UK
12h ago

Director of Information Technology

Zavation Medical Products
12h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)